Navigation Links
Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
Date:4/22/2013

SAN DIEGO, April 22, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that Michael Narachi , president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years.

PhRMA represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

"PhRMA represents an industry dedicated to the noblest of missions:  Improving the health of patients all over the world," said Narachi. "I'm honored to join the board of PhRMA, and I'm looking forward to being a part of an organization whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients."

"I am pleased to welcome a respected industry leader, Mike Narachi , to PhRMA's Board of Directors," said PhRMA President and CEO John J. Castellani . "Mike's many years of experience in the biopharmaceutical sector make him an invaluable addition to our Board as we continue to fight for public policies that recognize the true value of innovative medicines for both patients and the American economy."

Narachi has served as Orexigen's President and Chief Executive Officer and a member of Orexigen's board of directors since March 2009.

Before joining Orexigen, Narachi served as Chairman, CEO and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009, and chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Narachi left Amgen Inc., a leading therapeutics company, where he served as an officer and Vice President and, from 1999 through 2003, as General Manager of Amgen's Anemia Business. After joining Amgen in 1984, he held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. 

Mr. Narachi also currently serves as a member of the Board of Directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Contact: McDavid Stilwell , 858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
3. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
4. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
5. Michael Berman Joins InspireMD Board
6. Secretary of Department of Environmental Protection, Michael Krancer, to Facilitate Networking Session at Pittcon 2013
7. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
8. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
9. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
10. Sigma-Aldrich Elects Michael Marberry As Director
11. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... and PETACH TIKVAH, Israel , ... a leading developer of adult stem cell technologies for neurodegenerative ... Officer, will present at the Alliance for Regenerative Medicine,s (ARM) ... on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & Chief ...
(Date:4/19/2017)... ... 18, 2017 , ... The Vibrating Orifice Aerosol Generator (VOAG) ... monodisperse droplets of known diameters for research applications such as for calibrating droplet ... drying monodisperse droplets. , The VOAG requires forcing liquid out of an ...
(Date:4/19/2017)... ... , ... Alisa Wright, founder and CEO of Singota Solutions , has ... in Lafayette, Indiana. , The Distinguished Alumni Award was established in 1984 to ... scientific endeavors. , Wright began her career in the pharmaceutical industry with firms ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of ... Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis ... clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):